24/7 Market News Snapshot 25 April, 2025 – Mangoceuticals, Inc. Common Stock (NASDAQ:MGRX)

April 25, 2025

DENVER, Colo., 25 April, 2025 (www.247marketnews.com) – (NASDAQ:MGRX) are discussed in this article.
Mangoceuticals, Inc. (MGRX) is currently witnessing a challenging phase as its shares trade at $1.977 in the pre-market session, reflecting a decline of 5.86% from the previous closing price of $2.100. The notable trading volume of 2.24 million shares indicates increased activity among investors, suggesting a period of potential volatility. Technical indicators, including the Relative Strength Index (RSI) and moving averages, align with a bearish sentiment, hinting that a breach below critical support levels may lead to further declines, while resistance remains around the $2.10 mark. Investors are advised to closely observe these metrics to assess the likelihood of MGRX’s recovery or further downturns.

In a significant strategic initiative, Mangoceuticals has announced the acquisition of intellectual property and related assets from Smokeless Technology Corp. This acquisition positions the company to capitalize on the burgeoning oral pouch delivery market, which is rapidly growing within the health and wellness arena. Under the reputable brands MangoRx and PeachesRx, Mangoceuticals is focused on enhancing telemedicine solutions tailored to an array of health and wellness preferences.

With the incorporation of Smokeless Technology’s advanced pouch innovations—especially geared toward stimulant and functional formulations—Mangoceuticals aims to introduce a new line of products. This move will expand its offerings to include innovative non-pharmaceutical and nutraceutical solutions.

CEO Jacob Cohen highlighted the significance of this acquisition, noting it as a unique opportunity to tap into the expanding nutraceutical pouch delivery market, reinforcing the company’s dedication to health and wellness advancements. The demand for oral pouches is on the rise, with projections suggesting the global market may surpass $37.34 billion by 2032.

Additionally, the company is strengthening its management team with the appointment of Tim Corkum, an experienced leader with a background at JUUL Labs and Philip Morris International. His expertise will be essential as Mangoceuticals prepares to launch new products and incorporate distinctive stimulant formulations. By leveraging established distribution channels and innovative marketing approaches, Mangoceuticals is positioned to emerge as a leading player in the nutraceutical landscape, advancing its mission to provide impactful health solutions.

Related news for (MGRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.